The ability of the MD to reduce visceral adiposity while preserving LBM may have important implications in the context of semaglutide therapy, which is known to reduce overall fat but, in some rare cases, also to associate with a LBM loss [68, 69]
Patients with Graves' disease may develop type 2 diabetes independently or may experience weight gain following treatment for hyperthyroidism (with antithyroid drugs, radioactive iodine, or surgery), which can increase their risk of metabolic complications
It is worth noting that Rybelsus1 may potentially result in weight loss, which can be considered as a possible side effect
What to do: If you experience any of these mental changes, call your healthcare provider right away
This analysis used a population pharmacokinetic model of semaglutide to identify clinically relevant covariates for exposure
Weight reduction decreases stress on the knee joint and can improve pain and function in patients with obesity-related osteoarthritis